Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
RPRX's Cash to Debt is ranked higher than
97% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. RPRX: No Debt )
RPRX' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: No Debt

Equity to Asset 0.95
RPRX's Equity to Asset is ranked higher than
94% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RPRX: 0.95 )
RPRX' s 10-Year Equity to Asset Range
Min: 0.09   Max: 0.99
Current: 0.95

0.09
0.99
Interest Coverage No Debt
RPRX's Interest Coverage is ranked higher than
94% of the 382 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RPRX: No Debt )
RPRX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 45.27
M-Score: -3.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -464457.14
RPRX's Operating margin (%) is ranked lower than
100% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. RPRX: -464457.14 )
RPRX' s 10-Year Operating margin (%) Range
Min: -624550   Max: -101.1
Current: -464457.14

-624550
-101.1
Net-margin (%) -464457.14
RPRX's Net-margin (%) is ranked lower than
100% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. RPRX: -464457.14 )
RPRX' s 10-Year Net-margin (%) Range
Min: -624550   Max: -35.93
Current: -464457.14

-624550
-35.93
ROE (%) -61.95
RPRX's ROE (%) is ranked lower than
70% of the 754 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. RPRX: -61.95 )
RPRX' s 10-Year ROE (%) Range
Min: -336.72   Max: -2.72
Current: -61.95

-336.72
-2.72
ROA (%) -58.42
RPRX's ROA (%) is ranked lower than
76% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -23.16 vs. RPRX: -58.42 )
RPRX' s 10-Year ROA (%) Range
Min: -237.27   Max: -2.17
Current: -58.42

-237.27
-2.17
ROC (Joel Greenblatt) (%) -76679.25
RPRX's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: -344.23 vs. RPRX: -76679.25 )
RPRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -136170   Max: -226.32
Current: -76679.25

-136170
-226.32
EBITDA Growth (3Y)(%) 10.50
RPRX's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. RPRX: 10.50 )
RPRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -51.7   Max: 68.7
Current: 10.5

-51.7
68.7
EPS Growth (3Y)(%) 10.20
RPRX's EPS Growth (3Y)(%) is ranked higher than
67% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. RPRX: 10.20 )
RPRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -59   Max: 112.8
Current: 10.2

-59
112.8
» RPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

RPRX Guru Trades in Q2 2014

Steven Cohen 100,268 sh (unchged)
» More
Q3 2014

RPRX Guru Trades in Q3 2014

John Paulson 1,000,000 sh (New)
Steven Cohen Sold Out
» More
Q4 2014

RPRX Guru Trades in Q4 2014

Chuck Royce 251,000 sh (New)
John Paulson Sold Out
» More
Q1 2015

RPRX Guru Trades in Q1 2015

Chuck Royce 191,000 sh (-23.90%)
» More
» Details

Insider Trades

Latest Guru Trades with RPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.00
RPRX's P/B is ranked lower than
77% of the 713 Companies
in the Global Biotechnology industry.

( Industry Median: 3.32 vs. RPRX: 5.00 )
RPRX' s 10-Year P/B Range
Min: 0.7   Max: 85
Current: 5

0.7
85
P/S 22585.29
RPRX's P/S is ranked lower than
173% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: 7.28 vs. RPRX: 22585.29 )
RPRX' s 10-Year P/S Range
Min: 0   Max: 941.67
Current: 22585.29

0
941.67
Current Ratio 19.69
RPRX's Current Ratio is ranked higher than
90% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. RPRX: 19.69 )
RPRX' s 10-Year Current Ratio Range
Min: 0.23   Max: 66.45
Current: 19.69

0.23
66.45
Quick Ratio 19.69
RPRX's Quick Ratio is ranked higher than
90% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. RPRX: 19.69 )
RPRX' s 10-Year Quick Ratio Range
Min: 0.23   Max: 66.45
Current: 19.69

0.23
66.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.10
RPRX's Price/Net Cash is ranked higher than
56% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. RPRX: 5.10 )
RPRX' s 10-Year Price/Net Cash Range
Min: 0.45   Max: 84.15
Current: 5.1

0.45
84.15
Price/Net Current Asset Value 5.10
RPRX's Price/Net Current Asset Value is ranked higher than
56% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. RPRX: 5.10 )
RPRX' s 10-Year Price/Net Current Asset Value Range
Min: 0.43   Max: 224.36
Current: 5.1

0.43
224.36
Price/Tangible Book 5.10
RPRX's Price/Tangible Book is ranked lower than
67% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RPRX: 5.10 )
RPRX' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 100.57
Current: 5.1

0.42
100.57
Earnings Yield (Greenblatt) -22.00
RPRX's Earnings Yield (Greenblatt) is ranked lower than
98% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. RPRX: -22.00 )
RPRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -22   Max: 41501.3
Current: -22

-22
41501.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ZONN.Germany,
Repros Therapeutics Inc was organized on August 20, 1987. The Company is a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's main product candidate, Androxal, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. It is developing Androxal for men of reproductive age with low testosterone levels. Androxal treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. The Company's second product candidate, Proellex for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. The Company recently completed a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex. The Company's research and development activities, preclinical studies and clinical trials, and the manufacturing, marketing and labeling of any products it may develop, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries.
» More Articles for RPRX

Headlines

Articles On GuruFocus.com
comment on RPRX Mar 06 2013 
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
promotes testosteron Jun 22 2011 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
REPROS THERAPEUTICS INC. Financials May 15 2015
10-Q for Repros Therapeutics, Inc. May 10 2015
Repros Reports Narrower Y/Y Loss in Q1, Pipeline in Focus - Analyst Blog May 08 2015
What's in Store for Repros (RPRX) this Earnings Season? - Analyst Blog May 07 2015
Repros Therapeutics reports 1Q loss May 07 2015
Repros Therapeutics reports 1Q loss May 07 2015
REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition May 07 2015
Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results May 07 2015
10-K for Repros Therapeutics, Inc. May 04 2015
Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application Apr 15 2015
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 15 2015
Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application Apr 15 2015
REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events Apr 13 2015
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 08 2015
Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog Apr 07 2015
Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization... Apr 06 2015
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 06 2015
Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization... Apr 06 2015
Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog Apr 02 2015
Lumber Liquidators, CarMax are big market movers Apr 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK